SASMED <4263> announced its financial results for the fiscal year ending June 2024 on the 9th. Business revenue decreased by 35.4% from the previous year to 0.342 billion yen, operating loss was 0.364 billion yen (loss of 0.048 billion yen in the previous year), ordinary loss was 0.357 billion yen (loss of 0.044 billion yen in the same period), and net loss for the current period was 0.357 billion yen (loss of 0.05 billion yen in the same period).

The business revenue for the DTx product business was 0.2 billion yen (0.4 billion yen for the same period last year), and the segment profit was 0.055 billion yen (profit of 0.256 billion yen for the same period last year). In the development of therapeutic apps, we are preparing for insurance coverage and product launch for the insomnia treatment app. In addition, in the app for tinnitus treatment, which is being developed in collaboration with Kyorin Pharmaceutical Co., Ltd. <4569>, we have started a specific clinical trial and received a milestone of 0.1 billion yen due to the use of the app by the first subject. Regarding the milestone, we have recognized it as revenue in conjunction with the contract one-time payment of 0.1 billion yen, which we received and recorded as a contract liability at the time of contract conclusion. Furthermore, we have signed a contract with Asuka Pharmaceuticals for joint research and development of therapeutic apps in the obstetrics and gynecology field and sales after product launch, and have received a one-time payment of 0.2 billion yen as a contract one-time payment. There are no products currently in the sales phase.

The business revenue for the DTx platform business was 0.142 billion yen (0.13 billion yen for the same period last year), and the segment loss was 0.011 billion yen (profit of 0.066 billion yen for the same period last year).With respect to providing a clinical trial system, we are conducting a clinical trial using blockchain technology, which is the first in the world for corporate clinical trials, based on a contract for conducting clinical trials concluded with Accurys Pharma. Furthermore, in the specific clinical trial of the tinnitus treatment app that started in collaboration with Kyorin Pharmaceutical, we are using SUSMED SourceDataSync(R). Revenue from activities related to the provision of machine learning automatic analysis systems and support for DTx development is stable and supported by continued use.

For the fiscal year ending June 2025, we are forecasting business revenue of 0.479 billion yen, an increase of 39.9% compared to the previous year, an operating loss of 0.583 billion yen, an ordinary loss of 0.583 billion yen, and a net loss for the current period of 0.589 billion yen.